Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia

被引：21
|
作者：
Tamura, Akihiro [1 ]
Ishida, Toshiaki [1 ]
Saito, Atsuro [1 ]
Yamamoto, Nobuyuki [1 ]
Yokoi, Takehito [1 ,2 ]
Uemura, Suguru [1 ,3 ]
Nino, Nanako [1 ,3 ]
Fujiwara, Takahiro [1 ]
Tahara, Teppei [1 ]
Nakamura, Sayaka [1 ]
Kozaki, Aiko [1 ]
Kishimoto, Kenji [1 ]
Hasegawa, Daiichiro [1 ]
Kosaka, Yoshiyuki [1 ]
机构：
[1] Kobe Childrens Hosp, Childrens Canc Ctr, Dept Hematol & Oncol, Kobe, Hyogo, Japan
[2] Osaka Univ Hosp, Dept Pediat, Suita, Osaka, Japan
[3] Kobe Univ Hosp, Dept Pediat, Kobe, Hyogo, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷 / 10期
关键词：
acute myeloid leukemia; azacitidine; pediatric; post hematopoietic stem cell transplantation; CONVENTIONAL CARE REGIMENS; REGULATORY T-CELLS; MYELODYSPLASTIC SYNDROME; HYPOMETHYLATING AGENT; ELDERLY-PATIENTS; SALVAGE THERAPY; 5-AZA-2'-DEOXYCYTIDINE; MALIGNANCIES; DECITABINE; RELAPSE;
D O I：
10.1002/pbc.27284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The dismal prognosis of pediatric acute myeloid leukemia (AML) relapsing after hematopoietic stem cell transplantation (HSCT) requires exploration of novel strategies to prevent relapse. Azacitidine (AZA) maintenance therapy could potentially reduce the recurrence rate post HSCT. Here, we presents the cases of three children with high-risk AML post HSCT who were treated with low-dose AZA maintenance therapy, demonstrating the feasibility of this therapy. Currently, all three are in complete remission for 13-41 months despite their high-risk characteristics. Our encouraging data warrant larger prospective studies to assess the efficacy and safety of low-dose AZA maintenance therapy post HSCT for pediatric patients with high-risk AML.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Low-Dose Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation for High-Risk Pediatric Acute Myeloid Leukemia
    Tamura, A.
    Ishida, T.
    Saito, A.
    Yamamoto, N.
    Yokoi, T.
    Uemura, S.
    Nino, N.
    Nakamura, S.
    Kozaki, A.
    Kishimoto, K.
    Hasegawa, D.
    Kosaka, Y.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S191 - S191
  • [2] Low-dose decitabine as maintenance after allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia
    Bucalossi, Alessandro
    Tozzi, Monica
    Lenoci, Mariapia
    Toraldo, Francesca
    Del Re, Valeria
    Marotta, Giuseppe
    BONE MARROW TRANSPLANTATION, 2019, 54 : 170 - 170
  • [3] Low-Dose Azacitidine After Allogeneic Stem Cell Transplantation for Acute Leukemia
    Jabbour, Elias
    Giralt, Sergio
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Jagasia, Madan
    Kebriaei, Partow
    de Padua, Leandro
    Shpall, Elizabeth J.
    Champlin, Richard
    de Lima, Marcos
    CANCER, 2009, 115 (09) : 1899 - 1905
  • [4] Maintenance Therapy with Chidamide Plus Azacitidine after Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia Patients
    Hu, Xiaohui
    Wu, Depei
    Chen, Suning
    Wu, Yaxue
    Zhang, Yang
    Bai, Lian
    Wu, Bing
    Zhou, Haixia
    Xu, Mingzhu
    Jiang, Shanshan
    Qian, Chongsheng
    Xue, Shengli
    BLOOD, 2023, 142
  • [5] Post Hematopoietic Cell Transplantation Maintenance Therapy with Low-Dose Azacitidine in a Pediatric Population with High-Risk Myeloid Neoplasms
    Tarlock, Katherine
    Merkel, Emily C.
    Cooper, Todd
    Summers, Corinne
    Thakar, Monica
    Petrovic, Aleksandra
    Goshorn, Ross
    Irwin, Robert
    Gooley, Ted
    Bleakley, Marie
    Dahlberg, Ann
    BLOOD, 2023, 142
  • [6] Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia
    Ali, Naveed
    Tomlinson, Benjamin
    Metheny, Leland
    Goldstein, Steven C.
    Fu, Pingfu
    Cao, Shufen
    Caimi, Paolo
    Patel, Rushang D.
    Varela, Juan Carlos
    Andrade, Luisa
    Balls, Jason W.
    Baer, Linda
    Smith, Megan
    Smith, Tori
    Nelson, Megan
    de Lima, Marcos
    Mori, Shahram
    LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2839 - 2849
  • [7] Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome
    de Lima, Marcos
    Giralt, Sergio
    Thall, Peter F.
    Silva, Leandro de Padua
    Jones, Roy B.
    Komanduri, Krishna
    Braun, Thomas M.
    Nguyen, Hoang Q.
    Champlin, Richard
    Garcia-Manero, Guillermo
    CANCER, 2010, 116 (23) : 5420 - 5431
  • [8] Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia
    Ma, Yunju
    Qu, Changju
    Dai, Haiping
    Yin, Jia
    Li, Zheng
    Chen, Jia
    Qiu, Huiying
    Sun, Aining
    Miao, Miao
    Fu, Chengcheng
    Jin, Zhengming
    Zhu, Xiaming
    Wu, Depei
    Tang, Xiaowen
    BONE MARROW TRANSPLANTATION, 2020, 55 (06) : 1206 - 1208
  • [9] Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia
    Yunju Ma
    Changju Qu
    Haiping Dai
    Jia Yin
    Zheng Li
    Jia Chen
    Huiying Qiu
    Aining Sun
    Miao Miao
    Chengcheng Fu
    Zhengming Jin
    Xiaming Zhu
    Depei Wu
    Xiaowen Tang
    Bone Marrow Transplantation, 2020, 55 : 1206 - 1208
  • [10] Subcutaneous low-dose azacitidine as maintenance therapy following hematopoietic stem cell transplantation for acute myeloid leukemia and high-risk myelodysplastic syndrome-A propensity score matched analysis
    Americo, Andre Dias
    Silva, Cinthya Correa
    Kerbauy, Nassif
    Arcuri, Leonardo Javier
    Ribeiro, Andressa Alice Feitosa
    Hamerschlak, Nelson
    Santos, Fabio Pires Souza
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 : S427 - S430
12345